InVivoMAb Anti-Human PD-1 Antibody (Iv0209) (HS870020)

Name: InVivoMAb Anti-Human PD-1 Antibody (Iv0209)
Brand: abinScience
SKU: HS870020
Price: 370 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호

HS870020

설명

InVivoMAb Anti-Human CD279/PDCD1/PD1 Antibody (Iv0209) [Iv0209] (HS870020) is a mouse monoclonal antibody detecting Programmed cell death protein 1 in ELISA, Neutralization, FCM. Suitable for Human.

Highlights

●Multi-Application — Validated across multiple applications.
●Flow Cytometry — Validated for flow cytometry applications.

종 반응성

Human

응용 분야

ELISA, Neutralization, FCM

숙주 종

Mouse

클론성

Monoclonal

이소타입

IgG2a, kappa

클론 ID

Iv0209

타겟

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1

내독소 수준

< 1 EU/mg

순도

>95% as determined by SDS-PAGE.

관련 제품

pH 7.4 Dilution Buffer

정제

Protein A/G purified from cell culture supernatant.

등록번호

Q15116

형태

Liquid

저장 완충액

0.01M PBS pH 7.4.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

제품 사용 정보

응용 분야	희석
ELISA	1:2000-1:20000

안정성 및 저장

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

배경

Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo).

1. Fife, BT. et al. (2011) Annals of the New York Academy of Sciences 1217, 45-59. PMID: 21276005

2. Bardhan, K. et al. (2019) Scientific reports 9, 17252. PMID: 31754127

3. Patsoukis, N. et al. (2020) Communications biology 3, 128. PMID: 32184441

4. Xiao, X. et al. (2023) Nature communications 14, 2859. PMID: 37208329

5. Zak, KM. et al. (2015) Structure (London, England : 1993) 23, 2341-2348. PMID: 26602187

참고사항

For research use only. Not suitable for clinical or therapeutic use.

Isotype Control

Mouse IgG2a (Fc Silence) Recombinant Isotype Control (MOPC 173) (MF533023)

이미지